{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:51:23Z","timestamp":1782413483445,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,25]]},"DOI":"10.7759\/cureus.111496","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:30:20Z","timestamp":1782412220000},"source":"Crossref","is-referenced-by-count":0,"title":["Fatal Rapidly Progressive Interstitial Lung Disease in Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Dermatomyositis in a Brazilian Patient: A Case Report"],"prefix":"10.7759","author":[{"given":"Izabella","family":"Zgoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda A","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle C","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Y","family":"Kaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura P","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor L","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel A","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021, 12:773352. 10.3389\/fimmu.2021.773352","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00267-4","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","volume":"13","author":"Sehgal S","year":"2025","unstructured":"Sehgal S, Patel A, Chatterjee S, et al.. Idiopathic inflammatory myopathies related lung disease in adults. Lancet Respir Med. 2025, 13:272-88. 10.1016\/S2213-2600(24)00267-4","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji H","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, et al.. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020, 72:488-98. 10.1002\/art.41105","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151959","article-title":"Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review","volume":"53","author":"McPherson M","year":"2022","unstructured":"McPherson M, Economidou S, Liampas A, Zis P, Parperis K. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum. 2022, 53:151959. 10.1016\/j.semarthrit.2022.151959","journal-title":"Semin Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu X","year":"2024","unstructured":"Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2024, 20:48-62. 10.1038\/s41584-023-01054-9","journal-title":"Nat Rev Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08822-5","article-title":"Interstitial lung disease in anti-MDA5 positive dermatomyositis","volume":"60","author":"Wu W","year":"2021","unstructured":"Wu W, Guo L, Fu Y, et al.. Interstitial lung disease in anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol. 2021, 60:293-304. 10.1007\/s12016-020-08822-5","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model","volume":"158","author":"Lian X","year":"2020","unstructured":"Lian X, Zou J, Guo Q, et al.. Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model. Chest. 2020, 158:1535-45. 10.1016\/j.chest.2020.04.057","journal-title":"Chest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/9s7djz","article-title":"Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study","volume":"43","author":"Faria MS","year":"2025","unstructured":"Faria MS, Yoshida A, Mugii N, et al.. Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study. Clin Exp Rheumatol. 2025, 43:193-201. 10.55563\/clinexprheumatol\/9s7djz","journal-title":"Clin Exp Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1628748","article-title":"Risk factors for mortality in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease: a systematic review and meta-analysis","volume":"16","author":"Yang Y","year":"2025","unstructured":"Yang Y, Li Y, Yuan W, Zhang S, He X, Ji J. Risk factors for mortality in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease: a systematic review and meta-analysis. Front Immunol. 2025, 16:1628748. 10.3389\/fimmu.2025.1628748","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002770","article-title":"Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study","volume":"9","author":"Abe K","year":"2023","unstructured":"Abe K, Furuta S, Kobayashi Y, et al.. Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study. RMD Open. 2023, 9:e002770. 10.1136\/rmdopen-2022-002770","journal-title":"RMD Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03485-z","article-title":"Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease","volume":"27","author":"Zhao K","year":"2025","unstructured":"Zhao K, Zhang J, Kong Q, et al.. Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease. Arthritis Res Ther. 2025, 27:32. 10.1186\/s13075-025-03485-z","journal-title":"Arthritis Res Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (chest) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson SR","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, et al.. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (chest) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Care Res (Hoboken). 2024, 76:1051-69. 10.1002\/acr.25348","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/499000-fatal-rapidly-progressive-interstitial-lung-disease-in-anti-melanoma-differentiation-associated-gene-5-mda5-dermatomyositis-in-a-brazilian-patient-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:30:21Z","timestamp":1782412221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/499000-fatal-rapidly-progressive-interstitial-lung-disease-in-anti-melanoma-differentiation-associated-gene-5-mda5-dermatomyositis-in-a-brazilian-patient-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.111496","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}